Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.
Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.
Panelists discuss how the SHASTA-2 study evaluated the efficacy and safety of plozasiran in reducing triglyceride levels and APOC3 in familial chylomicronemia syndrome, comparing outcomes with the placebo group and assessing implications for treating severe hypertriglyceridemia and preventing pancreatitis.
Panelists discuss how a multidisciplinary approach enhances the management of familial chylomicronemia syndrome by fostering collaboration among clinicians to address unmet treatment needs and optimize patient outcomes, while also exploring existing treatment gaps that contribute to ongoing risks of acute pancreatitis and hospitalization.
Panelists discuss how early diagnosis and intervention in familial chylomicronemia syndrome (FCS) are crucial for preventing cardiovascular and metabolic complications, emphasizing the key role clinicians play in initiating timely and effective treatment strategies.
Panelists discuss how familial chylomicronemia syndrome (FCS) is characterized by severe hypertriglyceridemia and genetic mutations in the LPL gene, highlighting the key diagnostic criteria and complications, such as acute pancreatitis, while emphasizing the impact of untreated FCS on patient quality of life and long-term health risks.
Panelists discuss how familial chylomicronemia syndrome (FCS) imposes a significant economic burden on patients, affecting their ability to stay employed and manage the costs associated with long-term care and treatment.
After an acute coronary syndrome (ACS) event, elderly patients are at greater risk of death and nonfatal coronary events compared with younger patients. Despite this, elderly patients continue to receive less evidence-based therapy. Lipidlowering therapy with statins is now routine practice for the secondary prevention of coronary heart disease. Achieving the optional National Cholesterol Expert Panel goal of a low-density lipoprotein cholesterol level of < 70 mg/dL for ACS patients over 70 years of age could prevent nearly 80 deaths or nonfatal coronary events for every 1000 patients treated for 2 years with a number needed to treat of approximately 12.
September 10th 2008